MedTrace Logo

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

NCT04803994 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 434

Last updated 2025-01-07

No results posted yet for this study

Summary

The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC. Approximately 434 patients in two arms of treatment will be enrolled.

Conditions

Interventions

DRUG

Atezolizumab

1200 mg atezolizumab intravenously Q3W (max 32 cycles, up to 24 months)

DRUG

Bevacizumab

15 mg/kg intravenously Q3W (max 32 cycles, up to 24 months)

PROCEDURE

TACE

Locoregional therapy will be performed as a standard-of-care procedure

Sponsors & Collaborators

  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

    lead OTHER

Principal Investigators

  • Salah Eddin Al-Batran, Prof. Dr. · Institut für Klinische Krebsforschung IKF GmbH, Frankfurt, Germany

  • Peter Galle, Prof. Dr. · Universitätsmedizin Mainz, Germany

  • Jordi Bruix, Prof. Dr. · Barcelona Clinic Liver Cancer, Universitat de Barcelona, Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-06
Primary Completion
2027-07-31
Completion
2027-07-31

Countries

  • Austria
  • France
  • Germany
  • Italy
  • Japan
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04803994 on ClinicalTrials.gov